(Q46979428)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17898704%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

title

An association study of riluzole serum concentration and survival and disease progression in patients with ALS (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17898704%20AND%20SRC:MED&resulttype=core&format=json

amyotrophic lateral sclerosis

8 January 2020

main subject

1 reference

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17898704%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

author name string

Groeneveld GJ

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17898704%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

van Kan HJ

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17898704%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Lie-A-Huen L

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17898704%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

van den Berg LH

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17898704%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

language of work or name

English

0 references

publication date

26 September 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17898704%20AND%20SRC:MED&resulttype=core&format=json

Clinical Pharmacology & Therapeutics

8 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17898704%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

volume

83

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17898704%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17898704%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

page(s)

718-722

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17898704%20AND%20SRC:MED&resulttype=core&format=json

Natural history of ALS: symptoms, strength, pulmonary function, and disability

8 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100382

The pharmacology and mechanism of action of riluzole

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100382

Riluzole serum concentrations in patients with ALS: associations with side effects and symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100382

A clinical trial of creatine in ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100382

Voltage-activated sodium currents in a cell line expressing a Cu,Zn superoxide dismutase typical of familial ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100382

7 January 2021

A novel neuroprotective mechanism of riluzole: direct inhibition of protein kinase C.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100382

7 January 2021

Riluzole stimulates nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor synthesis in cultured mouse astrocytes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100382

7 January 2021

Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100382

7 January 2021

Pharmacogenetics and adverse drug reactions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100382

7 January 2021

Inter- and intraindividual variability of riluzole serum concentrations in patients with ALS.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100382

7 January 2021

A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100382

7 January 2021

Association between CYP1A2 activity and riluzole clearance in patients with amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100382

7 January 2021

Population pharmacokinetics of riluzole in patients with amyotrophic lateral sclerosis.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100382

7 January 2021

Impact of random and fixed (optimal) sampling approach on the Bayesian estimation of clearance.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100382

7 January 2021

Pentoxifylline in ALS: a double-blind, randomized, multicenter, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100382

7 January 2021

A randomized sequential trial of creatine in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100382

7 January 2021

El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100382

7 January 2021

A validated HPLC assay to monitor riluzole plasma or serum concentrations in patients with amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100382

7 January 2021

A comparison of three measures of disease progression in ALS

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100382

7 January 2021

MW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100382

7 January 2021

Identifiers

DOI

10.1038/SJ.CLPT.6100382

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17898704%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

1 reference